High variability of drug exposure: A biopharmaceutic risk factor for chronic rejection

被引:25
作者
Kahan, BD [1 ]
机构
[1] Univ Texas, Sch Med, Dept Surg, Div Organ Transplantat, Houston, TX 77030 USA
关键词
D O I
10.1016/S0041-1345(98)00737-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
引用
收藏
页码:1639 / 1641
页数:3
相关论文
共 18 条
[1]   EFFECTS OF AMLODIPINE, A LONG-ACTING DIHYDROPYRIDINE CALCIUM-ANTAGONIST IN AGING HYPERTENSION - PHARMACODYNAMICS IN RELATION TO DISPOSITION [J].
ABERNETHY, DR ;
GUTKOWSKA, J ;
WINTERBOTTOM, LM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (01) :76-86
[2]   The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients [J].
Barone, G ;
Chang, CT ;
Choc, MG ;
Klein, JB ;
Marsh, CL ;
Meligeni, JA ;
Min, DI ;
Pescovitz, MD ;
Pollak, R ;
Pruett, TL ;
Stinson, JB ;
Thompson, JS ;
Vasquez, E ;
Waid, T ;
Wombolt, DG ;
Wong, RL .
TRANSPLANTATION, 1996, 61 (06) :875-880
[3]   Mycophenolate mofetil - A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation [J].
Fulton, B ;
Markham, A .
DRUGS, 1996, 51 (02) :278-298
[4]   MICHAELIS-MENTEN KINETICS DETERMINE CYCLOSPORINE STEADY-STATE CONCENTRATIONS - A POPULATION ANALYSIS IN KIDNEY-TRANSPLANT PATIENTS [J].
GREVEL, J ;
POST, BK ;
KAHAN, BD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (06) :651-660
[5]  
HAUCK WW, 1992, INT J CLIN PHARM TH, V30, P181
[6]  
Ihara H, 1995, Int J Urol, V2, P151, DOI 10.1111/j.1442-2042.1995.tb00444.x
[7]  
KAHAN BD, 1995, TRANSPLANTATION, V59, P505
[8]   OPTIMIZATION OF CYCLOSPORINE THERAPY IN RENAL-TRANSPLANTATION BY A PHARMACOKINETIC STRATEGY [J].
KAHAN, BD ;
GREVEL, J .
TRANSPLANTATION, 1988, 46 (05) :631-644
[9]   Variable oral absorption of cyclosporine - A biopharmaceutical risk factor for chronic renal, allograft rejection [J].
Kahan, BD ;
Welsh, M ;
Schoenberg, L ;
Rutzky, LP ;
Katz, SM ;
Urbauer, DL ;
VanBuren, CT .
TRANSPLANTATION, 1996, 62 (05) :599-606
[10]  
KAHAN BD, 1997, 16 ANN M AM SOC TRAN